DELIVERY OF AN OCULAR AGENT
A method to ameliorate inflammatory effects by providing an anti-platelet derived growth factor (anti-PDGF) agent. In one embodiment the agent is imatinib. In another embodiment the agent is dasatinib. The method reduces the undesirable effects of post-surgical scarring, such as restenosis, because of the anti-inflammatory effect of the anti-PDGF agent. The method may be used in patients undergoing any type of surgery, such as cardiac surgery, ocular surgery, vascular surgery, etc.
1 . A method comprising administering an anti-platelet derived growth factor (anti-pdgf) agent to an individual at: risk for post-surgical scar formation, the anti-PDGF agent administered at a dose sufficient to provide an anti-inflammatory effect to reduce post-surgical scar formation in the individual.
2 . The method of claim 1 wherein the anti-PDGF agent is selected from the group consisting of imatinib, dasatinib, AMN107, and combinations thereof.
3 . The method of claim 1 wherein the anti-PDGF agent is administered in combination with at least one anti-vascular endothelial growth factor (anti-VEGF) agent.
4 . The method of claim 3 wherein the anti-VEGF agent is selected from the group consisting of bevacizumab, ranibizumab, pegaptanib, sunitinib maleate, TNP470, integrin av antagonists, 2-methoxyestradiol, paclitaxel, P38 mitogen activated protein kinase inhibitors, anti-VEGF siRNA, and combinations thereof.
5 . The method of claim 1 wherein the anti-PDGF agent is administered prophylactically.
6 . The method of claim 1 wherein the individual is at risk for restenosis.
7 . The method of claim 1 wherein the anti-PDGF agent is administered ocularly.
8 . The method of claim 1 wherein the anti-PDGF agent is administered systemically.
9 . Use of an anti-platelet-derived growth factor (anti-PDGF) agent in a biocompatible composition with at least one excipient for anti-inflammatory effect to reduce scar formation in an individual undergoing a surgical procedure.
10 . The use of claim 9 wherein the individual is undergoing a cardiac surgical procedure.
11 . The use of claim 9 wherein the individual is undergoing angioplasty.
12 . The use of claim 9 wherein the individual is undergoing stent insertion.
13 . The use of claim 9 wherein the individual is undergoing a vascular graft.
14 . The use of claim 9 wherein the anti-PDGF agent is imatinib.
15 . The use of claim 9 wherein the anti-PDGF agent is dasatinib.
16 . The use of claim 9 wherein the anti-PDGF agent is AMN107.